Issue Brief: Using Competition Law to Promote Access to Medicines and Related Health Technologies in Low- and Middle-income Countries. UNDP. (2017)

immage

Competition law is an important policy tool that LMICs can use to protect consumer welfare and promote industrial and economic development. It aims to restrict unfair business practices, and promote quicker introduction and increased availability of health technologies. The issue brief highlights key aspects of using competition law to promote access to health technologies from UNDP’s landmark publication “Using Competition Law to Promote Access to Health Technologies: A guidebook for low- and middle-income countries.” The issue brief intends to be a resource for policymakers, national competition authorities, national procurement agencies, health authorities, civil society and other actors who have an interest in understanding the critical role of competition authorities in promoting access to health technologies.

 

Keywords: HIV, TB, LMICs, access, medicines, laws

 

Download Publication

The Maternal Health Thematic Fund: Towards Equality in Access, Quality of Care and Accountability. UNFPA. (2017)

immage

This report highlights the key results achieved over Phase II of the MHTF, from 2014 to 2016, structured around the three cross-cutting principles of accountability, equality of access and quality of care, as outlined in the MHTF Business Plan Phase II (2014-2017). The report foregrounds the MHTF’s role in supporting health systems strengthening, and addresses its catalytic nature, its promotion of sustainability and its strong emphasis on advancing innovation.


Keywords: health care, women, girls, human rights, gender

 

Download Publication

Global Hepatitis Report, 2017. WHO. (2017)

immage

This WHO Global hepatitis report describes, for the first time, the global and regional estimates on viral hepatitis in 2015, setting the baseline for tracking progress in implementing the new global strategy.

 

The report focuses on hepatitis B and C, which are responsible for 96% of all hepatitis mortality. It presents data along the five strategic directions (strategic information, interventions, equity, financing and innovation) – key pillars of the GHSS to facilitate monitoring of progress in countries, regions and globally, and to measure the impact of interventions on reducing new infections and saving lives between 2015 and 2030. 


Keywords: HIV, HCV, HBV, prevention, testing, treatment

 


Download Global Hepatitis Report 2017

 

Download Executive Summary

 

Regional Action Plan for Viral Hepatitis in South-East Asia, 2016–2021. WHO, Regional Office for South-East Asia. (2017)

immage

Viral hepatitis now ranks as the seventh leading cause of mortality worldwide. Although mortality due to communicable diseases has declined globally, the absolute burden and relative ranking of viral hepatitis as a cause of mortality has increased between 1990 and 2013.

 

Viral hepatitis causes at least as many, if not more, deaths annually compared with TB, AIDS, or malaria. Mortality due to viral hepatitis is increasing with time, while that due to TB, HIV and malaria is declining. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections account for more than 90% of viral hepatitis-related deaths and disability, with hepatitis A and E being responsible for the remaining.

 


Keywords: HIV, TB, hepatitis, viral, prevention and control, public health, vaccination

 

Download Publication

HIV Drug Resistance Report 2017. WHO. (2017)

immage

This second HIVDR report provides an update on recent population levels of HIVDR covering the period 2014–2016. The report includes data from 16 nationally representative surveys from 14 countries estimating resistance in: adults initiating ART (PDR), children younger than 18 months newly diagnosed with HIV, and adults on ART (acquired HIV drug resistance or ADR).

To contextualize results from representative HIVDR surveys, the report is supported by systematic reviews of the published literature on PDR in adults, children and adolescents, and ADR in paediatric and adult populations. 


Keywords: HIV, ART, drug resistance, treatment, prevalence


Downloads

 

- HIV drug resistance report 2017

 

- Access policy brief: Tackling HIV drug resistance: trends, guidelines and global action

Strategic Framework for Prevention of Parent to Child Transmission (PPTCT) of HIV in Pakistan. Khan A. (2017)

immage

This strategic framework provides a road map to scale-up PPTCT services in the most efficient manner, where value for money is achieved with the promise that no infected mother will be missed and no child will be born with HIV, where every HIV exposed infant will receive the much needed HIV test at 6 weeks of age, and linked to treatment where required.

 


Keywords: HIV, PPTCT, ART, treatment, care

 

Download Publication

Global Action Plan on HIV Drug Resistance 2017–2021. WHO. (2017)

immage

Preventing and managing the emergence of HIVDR is a key component of a comprehensive and effective HIV response, and should be integrated into broader efforts to ensure sustainability and greatest impact. It is essential that actions to monitor, prevent and respond to HIVDR are implemented at the clinical, programme and policy levels to address the many drivers of HIVDR.

The goal of this Global Action Plan is to articulate synergistic actions that will be required to prevent HIVDR from undermining efforts to achieve global targets on health and HIV, and to provide the most effective treatment to all people living with HIV including adults, key populations, pregnant and breastfeeding women, children and adolescents. 

 


Keywords: HIV, prevention, response, monitoring, surveillance

 

 

Download Publication

Factsheet: Unitaid and Hepatitis C in the Context of Co-infection with HIV. UNITAID. (2017)

immage

According to the WHO, about 2.3 million people are co-infected with HIV and the hepatitis C virus (HCV). Moreover, there were an estimated 1.75 million new hepatitis C virus (HCV) infections worldwide in 2015. HCV usually presents only mild symptoms, if any, until it is at an advanced stage, thereby making it difficult to recognize the disease early.


Keywords: HIV, HCV, diagnosis, treatment

 

 

Download Publication

Antimicrobial Resistance in the Asia Pacific Region: A Development Agenda. WHO, Regional Office for the Western Pacific. (2017)

immage

This report provides in-depth technical discussions in areas that have direct implications to the containment of AMR as a development agenda. The report is organized in five chapters which served as the technical background documents for the Biregional Technical Consultation on AMR in Asia, 14-15 April 2016. More information from the meeting is available in the WHO Meeting Report: Biregional Technical Consultation on Antimicrobial Resistance in Asia. The meeting was the first time senior officials from the Ministry of Health and Ministry of Agriculture across Asia came together to tackle AMR.

 

Keywords: drug resistance, microbial, infection control

 

 

Download Publication

At the Edge of a Miracle: The Hepatitis C Virus (HCV) Epidemic in Malaysia. Rahman F. (2017)

immage

The hepatitis C virus (HCV) has long since been a neglected disease, given long latency periods before any chronic illness manifests, and the low cure rate and numerous side effects of the pegylated interferon-ribavirin treatment (hereinafter PEGINF). However, of late, given the development of revolutionary drugs called direct-acting antivirals (DAAs) that can cure the disease in as little as 8 weeks, international interest, and with it, international financial investment, has peaked.


Keywords: HIV/HCV, co-infection, diagnostic, testing, treatment

 

Download Publication

Pages

database
Highlighted publications
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Cambodia_Estimations_and_projections_of_HIV_AIDS_at_Sub-national_level_2016-2020.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_HIV_drug_resistance_report_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Guidelines_on_public_health_response_to_pretreatment_HIV_drug_resistance_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Guidelines_for_Managing_Advanced_HIV_Disease_and_Rapid_Initiation_of_ART_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_What_New_in_Treatment_Monitoring_Viral_Load_and_CD4_Testing_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Pakistan_IBBS_2016-17.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Pakistan_Mapping_Key_Populations_2015-16.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_Global_AIDS_Update_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_Global_AIDS_Update_2017_Data_2017_en.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Myanmar_National_Strategic_Plan_on_HIV_and_AIDS_2016-2020.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_2017_Global_AIDS_Monitoring_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Nepal-IBBS-FIDU-Kathmandu-valley-RI-2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_methods_for_deriving_estimates_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/2015_Size_Estimation_of_Key_Affected_Populations_in_Philippines.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Assessment_of_Decentralization_of_ART_in_MMR_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS-2016-prevention-gap-report_en.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_Biomedical_AIDS_research_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Implementing_comprehensive_HIV_and_STI_programmes_with_transgender_people_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_cities_ending_the_aids_epidemic_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Philippines_2015_IHBSS_Factsheets.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Integrating_collaborative_TB_and_HIV_services_within_a_comprehensive_package_of_care_for_PWID_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/India_IBBS_report_2014-15.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/India_HSS_report_2014-15.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/2015_young_people_drugs_en.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Transforming_our_world_2015_UN.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Consolidated_on_the_use_of_antiretroviral_drugs_for_treating_and_preventing_HIV_infection_2016.pdf
Calendar of events